{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:53:01Z","timestamp":1761519181346},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,3,13]]},"abstract":"<jats:p> PURPOSE: Docetaxel and vinorelbine are active agents in advanced non\u2013small-cell lung cancer (NSCLC) and demonstrate preclinical synergism perhaps, in part, through their inactivation of the proto-oncogene bcl-2. We show that docetaxel (60 mg\/m<jats:sup>2<\/jats:sup>) and vinorelbine (45 mg\/m<jats:sup>2<\/jats:sup>) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed. <\/jats:p><jats:p> PATIENTS AND METHODS: Thirty-five chemotherapy na\u00efve patients with advanced NSCLC received vinorelbine as an intravenous push immediately followed by docetaxel as a 1-hour intravenous infusion once every 2 weeks. Prophylactic corticosteroids, ciprofloxacin, and filgrastim were used. <\/jats:p><jats:p> RESULTS: We delivered median doses of 450 mg\/m<jats:sup>2<\/jats:sup> of vinorelbine and 600 mg\/m<jats:sup>2<\/jats:sup> of docetaxel. The major objective response rate was 51% (95% confidence interval [CI], 34% to 68%). With a median follow-up of 14 months, the predicted median survival time was 14 months, and the 1-year survival rate was 60% (95% CI, 44% to 80%). Febrile neutropenia occurred in five patients and five (1.3%) of 384 treatments. No dose-limiting neurotoxicity occurred. Symptomatic onycholysis and excessive lacrimation were observed after several months or more of therapy. <\/jats:p><jats:p> CONCLUSION: Docetaxel 60 mg\/m<jats:sup>2<\/jats:sup> and vinorelbine 45 mg\/m<jats:sup>2<\/jats:sup>, both given every 2 weeks, is a highly active combination for the treatment of advanced NSCLC. Filgrastim largely obviates neutropenic fever and allows for the single-agent dose-intensity of both drugs to be delivered. The occurrence of certain late toxicities can limit use in some cases and suggests that the combination could also be beneficial in settings requiring briefer, fixed periods of treatment, such as in induction or postoperative therapy. <\/jats:p>","DOI":"10.1200\/jco.2000.18.6.1346","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:16:39Z","timestamp":1487920599000},"page":"1346-1350","source":"Crossref","is-referenced-by-count":46,"title":["Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1200","volume":"18","author":[{"given":"Vincent A.","family":"Miller","sequence":"first","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth K.","family":"Ng","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pizzo","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Perez","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Heelan","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[{"name":"From the Thoracic Oncology ServiceDivision of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0159","unstructured":"Haldar  S,  Basu  A,  Croce  C:  Bcl2 is the guardian of microtubule integrity.  Cancer Res 57:229,1997-233,"},{"key":"R3-0159","unstructured":"Miller  VA,  Kris  MG:  Vinorelbine for the treatment of advanced non-small cell lung cancer.  Med Lett Drugs Ther 37:72,1995-73,"},{"key":"R4-0159","unstructured":"Bissery  MC,  Vrignaud  P,  Bayssas  M, et al:  Preclinical in vivo activity of docetaxel-containing combinations.  Proc Am Soc Clin Oncol 14:489,1995  (abstr 1599)"},{"key":"R5-0159","unstructured":"Aoe  K,  Ueoka  H,  Kiura  K, et al:  Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line.  Proc Am Assoc Cancer Res 37:375,1996  (abstr 2560)"},{"key":"R6-0159","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.14.1072"},{"key":"R7-0159","unstructured":"Botta  M,  Arboscello  E,  Lerza  R, et al:  Effects of docetaxel on the in vitro growth of human myeloid progenitors.  Anticancer Res 19:1855,1999-1858,"},{"key":"R8-0159","unstructured":"Aoe  K,  Kiura  K,  Ueoka  H, et al:  Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.  Anticancer Res 19:291,1999-300,"},{"key":"R9-0159","unstructured":"Miller  V,  Grant  S,  Ng  K, et al:  Phase I trial of docetaxel (DTX) and vinorelbine (VNR) with filgrastim in patients with advanced non-small cell lung cancer (NSCLC).  Proc Am Soc Clin Oncol 17:471a,1998,  (abstr 1813)"},{"key":"R10-0159","unstructured":"Kris  MG,  Gralla  RJ,  Kalman  LA, et al:  Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.  Cancer Treat Rep 69:387,1985-395,"},{"key":"R11-0159","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197909)44:3<1125::AID-CNCR2820440348>3.0.CO;2-4"},{"key":"R12-0159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2677"},{"key":"R13-0159","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"R14-0159","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y"},{"key":"R15-0159","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.6.1779"},{"key":"R16-0159","doi-asserted-by":"crossref","unstructured":"Ramanathan  RK,  Belani  CP,  Reddy  VV:  Transient pulmonary infiltrates:  A hypersensitivity reaction to paclitaxel. Ann Intern Med 124:278,1996  (letter)","DOI":"10.7326\/0003-4819-124-2-199601150-00030"},{"key":"R18-0159","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2083::AID-CNCR6>3.0.CO;2-I"},{"key":"R19-0159","unstructured":"Blagosklonny  MV,  Schulte  T,  Nguyen  P, et al:  Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.  Cancer Res 56:1851,1996-1854,"},{"key":"R20-0159","unstructured":"Klaubner  N,  Parangi  S,  Flynn  E, et al:  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.  Cancer Res 57:81,1997-86,"},{"key":"R21-0159","unstructured":"Strobel  T,  Kraeft  S-K,  Chen  LB, et al:  BAX expression is associated with enhanced intracellular accumulation of paclitaxel:  A novel role for BAX during chemotherapy-induced cell death. Cancer Res 58:4776,1998-4781,"},{"key":"R22-0159","unstructured":"Kris  M,  Gralla  R,  Wertheim  M, et al:  Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.  Cancer Treat Rep 70:1091,1986-1096,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.6.1346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:43:20Z","timestamp":1653515000000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.6.1346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,13]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,3,13]]}},"alternative-id":["10.1200\/JCO.2000.18.6.1346"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.6.1346","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,13]]}}}